JaredSpitzMD
@JSpitz_MD
Followers
394
Following
2K
Media
32
Statuses
1K
Osler IM resident. Cornell Cardio Fellow. Inova Cardiology. CV prevention and lipids.
Washington, DC
Joined October 2018
’Tis the season for cardiometabolic thinking! 🎄 In this Fellow’s Voice piece, key insights on cardiometabolic care and prevention are shared to inform your practice and patient conversations. 🔗 https://t.co/ZgannKuZlj
#CardioCare #PreventiveCardiology #HeartHealth
0
11
44
Check out my latest article: Building a Smarter Lipid & CKM Clinic: Evidence-Based Workflow, Lifestyle First, and Cost-Effective Care https://t.co/z9y7UD6TYS via @LinkedIn
linkedin.com
Managing cholesterol isn’t just about numbers—it’s about reducing lifetime cardiovascular risk through a structured, patient-centered approach. At Intermountain Health, our Lipid & CKM Clinic uses...
0
1
2
This Pennsylvania barbershop boosts kids' confidence by paying young customers $3 to read stories aloud during haircuts, deserving endless retweets.
533
15K
87K
0
3
5
▶️ Key findings from a recent expert review on how elevated lipoprotein(a) drives peripheral arterial disease—and what emerging therapies could mean for the future of treatment. 📖 Watch & learn why Lp(a) screening matters. To read the publication, visit: https://t.co/MEV8HwdCFu
1
1
18
Check out my latest article: The Enduring Value of Coronary Artery Calcium Scoring in Cardiovascular Prevention https://t.co/xWttOuXjcl via @LinkedIn
linkedin.com
In an era of advanced cardiac imaging, coronary artery calcium (CAC) scoring remains the most powerful and practical tool for personalizing cardiovascular prevention. While coronary CT angiography...
0
1
3
Just out, Great work by the JACC Imaging team along with many others...I think this will be very helpful to guide AI-CPA... Great work @RonBlankstein @JACCJournals @ToddVillinesMD @MarosFerencik @JonathonLeipsic @YChandr72563556
https://t.co/Dy73eEzd23
0
24
79
We conducted a multi-center study from UC San Diego BEACON to evaluate real-world lowering of Lp(a) with PCSK9i and predictors of response 🧵 below @EJPCEiC @UCSDCardiology @UCSDCardFellows @ESC_Journals @MWilkinsonMD @PamTaubMD @MattRamsisMD
https://t.co/cgQm7zIvpE
academic.oup.com
AbstractAims. With no currently available targeted therapies for lipoprotein(a) [Lp(a)] lowering, proprotein convertase subtilisin/kexin type 9 inhibitors
1
5
19
The discovery of PCSK9: a turning point in cardiovascular prevention This state-of-the-art review describes how the discovery of PCSK9 (proprotein convertase subtilisin/kexin type 9)fundamentally reshaped our understanding and treatment of atherosclerotic cardiovascular disease
3
18
57
excited to co chair this session with @DrMarthaGulati and learn more about #menopause #cv health from our expert panel!
0
2
9
A decade of work. One mission. Today: FDA approval. Our novel therapy was designed to help millions of patients finally reach their LDL-C goals. Grateful to our trial participants, FDA, and our team. https://t.co/soYy5mLRJo
#FDAApproval #PCSK9 #Cardiovascular
0
4
7
What a fantastic #EACVI2025. So many favs:: ➡️ Multiparametric AI scores are here. Embrace them. ➡️ Implementation is a shared challenge and opportunity. ➡️ CV Imaging guides excellence! Check full house #CardioOnc talk👇 ➡️ Cherish science and friendships.
5
1
9
Excellent viewpoint by Drs. Sohail Zahid @JackieYaoMD @MichaelJBlaha @CiccaroneCenter @hopkinsheart #🥍🫀🐦🏀⚾️🏈⚽️🎾
💬 Viewpoint: New #Obesity guidelines recommend direct adiposity measures, staging by obesity-related complications, explicit weight loss goals, and guidance on pharmacotherapy to advance personalized, risk-based care. https://t.co/mBqLUSPWdZ
1
10
35
Do clinical trials expire? New heart attack studies show that evidence from the 1980s may not apply to patients in 2025. Beta blockers are a case study in how medicine evolves, and how slowly our evidence base often keeps up. My latest Substack: https://t.co/VuGqbqdsRq
2
18
47
Welcome to @khurramn1, who is now serving as Editor-in-Chief of @AJPCardio! Thank you to @ErinMichos & @DrNathanWong for their outstanding leadership. Make sure to read the latest issue🫀 https://t.co/xY5t1qJkQs #PreventiveCardiology #ASPC #AJPC
15
23
104
Unique, challenging case of homozygous familial hypercholesterolemia (HoFH) Proud of our team @UCSDHealth! https://t.co/xsk2XNdf96
@sawyeraygani @AlexVaioSykesMD
@JACCJournals @PamelaBMorris @nationallipid @ASPCardio @FamilyHeartFdn @PamTaubMD @CBallantyneMD @MichaelDShapiro
1
2
10
New Concise Clinical Guidance from @ACCinTouch shows how Front of Packaging nutrition labeling facilitates faster, healthier choices at the point of purchase. Urges support for FDA-led initiative @DrDastmalchi
https://t.co/ppVIWq14OY
0
7
10
@AnaBaracCardio ⭐️ has led the cardioonc field & speaking on #CVrisk assessment of female oncology patients #CVprev #cardiotwitter ♥️ HF risk can occur throughout the duration and after tx ♥️⤴️ survivorship of Breast Cancer ♥️⤵️ risk of recurrence of Breast Cancer ♥️any with
1
10
34
🔥Powerful messages from #CVprev guru @DrMarthaGulati showing the gaps in care. Women deserve data-driven approach and the time is now.. Great partnerships showing the path @JACCJournals @ASPCardio @HFSA @AHAScience @WomenAs1 @cvi_phila
0
11
28
Beyond thrilled for this publication highlighting the importance of nutrition with patient education in reducing #cvd
https://t.co/E9KyCNF4H1
@cardio10s @PanjrathG Monica Aggarwal @rinaagustinaja Keith Ferdinand @NicoleLohrMD
jacc.org
https://t.co/PYPfw5XMbE
@uofl @UofLMedicine @ACCinTouch @UofLHealth Big day for Cardiology - - if everyone reads and adopts these principles, we can save our patients, save our healthcare system. Top 10 Things We Need to Know About This Article! Front-of-Package (FOP)
1
3
11